Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease
Identifieur interne : 002D74 ( Main/Corpus ); précédent : 002D73; suivant : 002D75Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease
Auteurs : S M Hague ; S. Klaffke ; O. BandmannSource :
- Journal of Neurology, Neurosurgery & Psychiatry [ 0022-3050 ] ; 2005-08.
English descriptors
- KwdEn :
Abstract
Parkinson’s disease and Huntington’s disease are both model diseases. Parkinson’s disease is the most common of several akinetic-rigid syndromes and Huntington’s disease is only one of an ever growing number of trinucleotide repeat disorders. Molecular genetic studies and subsequent molecular biological studies have provided fascinating new insights into the pathogenesis of both disorders and there is now real hope for disease modifying treatment in the not too distant future for patients with Parkinson’s disease or Huntington’s disease.
Url:
DOI: 10.1136/jnnp.2004.060186
Links to Exploration step
ISTEX:D540A881E7B65944EF4F038D17C4DC24937CAE4CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease</title><author><name sortKey="Hague, S M" sort="Hague, S M" uniqKey="Hague S" first="S M" last="Hague">S M Hague</name><affiliation><mods:affiliation>Academic Neurology Unit, Division of Genomic Medicine, University of Sheffield, UK</mods:affiliation></affiliation></author><author><name sortKey="Klaffke, S" sort="Klaffke, S" uniqKey="Klaffke S" first="S" last="Klaffke">S. Klaffke</name><affiliation><mods:affiliation>Academic Neurology Unit, Division of Genomic Medicine, University of Sheffield, UK</mods:affiliation></affiliation></author><author><name sortKey="Bandmann, O" sort="Bandmann, O" uniqKey="Bandmann O" first="O" last="Bandmann">O. Bandmann</name><affiliation><mods:affiliation>Academic Neurology Unit, Division of Genomic Medicine, University of Sheffield, UK</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D540A881E7B65944EF4F038D17C4DC24937CAE4C</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1136/jnnp.2004.060186</idno><idno type="url">https://api.istex.fr/document/D540A881E7B65944EF4F038D17C4DC24937CAE4C/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002D74</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease</title><author><name sortKey="Hague, S M" sort="Hague, S M" uniqKey="Hague S" first="S M" last="Hague">S M Hague</name><affiliation><mods:affiliation>Academic Neurology Unit, Division of Genomic Medicine, University of Sheffield, UK</mods:affiliation></affiliation></author><author><name sortKey="Klaffke, S" sort="Klaffke, S" uniqKey="Klaffke S" first="S" last="Klaffke">S. Klaffke</name><affiliation><mods:affiliation>Academic Neurology Unit, Division of Genomic Medicine, University of Sheffield, UK</mods:affiliation></affiliation></author><author><name sortKey="Bandmann, O" sort="Bandmann, O" uniqKey="Bandmann O" first="O" last="Bandmann">O. Bandmann</name><affiliation><mods:affiliation>Academic Neurology Unit, Division of Genomic Medicine, University of Sheffield, UK</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title><title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title><idno type="ISSN">0022-3050</idno><idno type="eISSN">1468-330X</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2005-08">2005-08</date><biblScope unit="volume">76</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1058">1058</biblScope></imprint><idno type="ISSN">0022-3050</idno></series><idno type="istex">D540A881E7B65944EF4F038D17C4DC24937CAE4C</idno><idno type="DOI">10.1136/jnnp.2004.060186</idno><idno type="href">jnnp-76-1058.pdf</idno><idno type="PMID">16024878</idno><idno type="local">0761058</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-3050</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>A-S, α-synuclein</term><term>CBP, CREB binding protein</term><term>COX2, cyclo-oxygenase 2</term><term>Huntington’s disease</term><term>MPTP, 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine</term><term>Parkinson’s disease</term><term>genetics</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson’s disease and Huntington’s disease are both model diseases. Parkinson’s disease is the most common of several akinetic-rigid syndromes and Huntington’s disease is only one of an ever growing number of trinucleotide repeat disorders. Molecular genetic studies and subsequent molecular biological studies have provided fascinating new insights into the pathogenesis of both disorders and there is now real hope for disease modifying treatment in the not too distant future for patients with Parkinson’s disease or Huntington’s disease.</div></front></TEI><istex><corpusName>bmj</corpusName><author><json:item><name>S M Hague</name><affiliations><json:string>Academic Neurology Unit, Division of Genomic Medicine, University of Sheffield, UK</json:string></affiliations></json:item><json:item><name>S Klaffke</name><affiliations><json:string>Academic Neurology Unit, Division of Genomic Medicine, University of Sheffield, UK</json:string></affiliations></json:item><json:item><name>O Bandmann</name><affiliations><json:string>Academic Neurology Unit, Division of Genomic Medicine, University of Sheffield, UK</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Review</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Drugs: CNS (not psychiatric)</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>A-S, α-synuclein</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>COX2, cyclo-oxygenase 2</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>CBP, CREB binding protein</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>MPTP, 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>genetics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Huntington’s disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson’s disease</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Parkinson’s disease and Huntington’s disease are both model diseases. Parkinson’s disease is the most common of several akinetic-rigid syndromes and Huntington’s disease is only one of an ever growing number of trinucleotide repeat disorders. Molecular genetic studies and subsequent molecular biological studies have provided fascinating new insights into the pathogenesis of both disorders and there is now real hope for disease modifying treatment in the not too distant future for patients with Parkinson’s disease or Huntington’s disease.</abstract><qualityIndicators><score>5.819</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>9</keywordCount><abstractCharCount>543</abstractCharCount><pdfWordCount>4895</pdfWordCount><pdfCharCount>34893</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>77</abstractWordCount></qualityIndicators><title>Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease</title><pmid><json:string>16024878</json:string></pmid><genre><json:string>review-article</json:string></genre><host><volume>76</volume><pages><first>1058</first></pages><issn><json:string>0022-3050</json:string></issn><issue>8</issue><genre></genre><language><json:string>unknown</json:string></language><eissn><json:string>1468-330X</json:string></eissn><title>Journal of Neurology, Neurosurgery & Psychiatry</title></host><publicationDate>2005</publicationDate><copyrightDate>2005</copyrightDate><doi><json:string>10.1136/jnnp.2004.060186</json:string></doi><id>D540A881E7B65944EF4F038D17C4DC24937CAE4C</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/D540A881E7B65944EF4F038D17C4DC24937CAE4C/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/D540A881E7B65944EF4F038D17C4DC24937CAE4C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/D540A881E7B65944EF4F038D17C4DC24937CAE4C/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease</title><respStmt xml:id="ISTEX-API" resp="Références bibliographiques récupérées via GROBID" name="ISTEX-API (INIST-CNRS)"></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>BMJ Publishing Group Ltd</publisher><availability><p>BMJ</p></availability><date>2005-07-15</date></publicationStmt><notesStmt><note>Correspondence to:
Dr Oliver Bandmann
Academic Neurology Unit, E Floor Medical School, Beech Hill Road, Sheffield S10 2RX, UK; o.bandmann@sheffield.ac.uk</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease</title><author><persName><forename type="first">S M</forename><surname>Hague</surname></persName><affiliation>Academic Neurology Unit, Division of Genomic Medicine, University of Sheffield, UK</affiliation></author><author><persName><forename type="first">S</forename><surname>Klaffke</surname></persName><affiliation>Academic Neurology Unit, Division of Genomic Medicine, University of Sheffield, UK</affiliation></author><author><persName><forename type="first">O</forename><surname>Bandmann</surname></persName><affiliation>Academic Neurology Unit, Division of Genomic Medicine, University of Sheffield, UK</affiliation></author></analytic><monogr><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title><title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title><idno type="pISSN">0022-3050</idno><idno type="eISSN">1468-330X</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2005-08"></date><biblScope unit="volume">76</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1058">1058</biblScope></imprint></monogr><idno type="istex">D540A881E7B65944EF4F038D17C4DC24937CAE4C</idno><idno type="DOI">10.1136/jnnp.2004.060186</idno><idno type="href">jnnp-76-1058.pdf</idno><idno type="PMID">16024878</idno><idno type="local">0761058</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2005-07-15</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Parkinson’s disease and Huntington’s disease are both model diseases. Parkinson’s disease is the most common of several akinetic-rigid syndromes and Huntington’s disease is only one of an ever growing number of trinucleotide repeat disorders. Molecular genetic studies and subsequent molecular biological studies have provided fascinating new insights into the pathogenesis of both disorders and there is now real hope for disease modifying treatment in the not too distant future for patients with Parkinson’s disease or Huntington’s disease.</p></abstract><textClass><keywords scheme="keyword"><list><head>hwp-journal-coll</head><item><term>Drugs: CNS (not psychiatric)</term></item></list></keywords></textClass><textClass xml:lang="en"><keywords scheme="keyword"><list><head>ABR</head><item><term>A-S, α-synuclein</term></item><item><term>COX2, cyclo-oxygenase 2</term></item><item><term>CBP, CREB binding protein</term></item><item><term>MPTP, 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine</term></item></list></keywords></textClass><textClass xml:lang="en"><keywords scheme="keyword"><list><head>KWD</head><item><term>genetics</term></item><item><term>Huntington’s disease</term></item><item><term>Parkinson’s disease</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2005-07-15">Created</change><change when="2005-08">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-3-14">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/D540A881E7B65944EF4F038D17C4DC24937CAE4C/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus bmj" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="no"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" URI="archivearticle.dtd" name="istex:docType"></istex:docType><istex:document><article xml:lang="en" article-type="review-article"><front><journal-meta><journal-id journal-id-type="hwp">jnnp</journal-id><journal-id journal-id-type="nlm-ta">J Neurol Neurosurg Psychiatry</journal-id><journal-title>Journal of Neurology, Neurosurgery & Psychiatry</journal-title><abbrev-journal-title abbrev-type="publisher">J Neurol Neurosurg Psychiatry</abbrev-journal-title><issn pub-type="ppub">0022-3050</issn><issn pub-type="epub">1468-330X</issn><publisher><publisher-name>BMJ Publishing Group Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="other">0761058</article-id><article-id pub-id-type="doi">10.1136/jnnp.2004.060186</article-id><article-id pub-id-type="other">jnnp;76/8/1058</article-id><article-id pub-id-type="pmid">16024878</article-id><article-id pub-id-type="other">1058</article-id><article-id pub-id-type="other">jnnp.2004.060186</article-id><article-categories><subj-group subj-group-type="heading"><subject content-type="original">Review</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>Drugs: CNS (not psychiatric)</subject></subj-group></article-categories><title-group><article-title>Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hague</surname><given-names>S M</given-names></name><xref rid="AFF1"></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Klaffke</surname><given-names>S</given-names></name><xref rid="AFF1"></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bandmann</surname><given-names>O</given-names></name><xref rid="AFF1"></xref></contrib><aff id="AFF1">Academic Neurology Unit, Division of Genomic Medicine, University of Sheffield, UK</aff></contrib-group><author-notes><corresp>Correspondence to:
Dr Oliver Bandmann
Academic Neurology Unit, E Floor Medical School, Beech Hill Road, Sheffield S10 2RX, UK; <ext-link xlink:href="o.bandmannsheffield.ac.uk" ext-link-type="email" xlink:type="simple">o.bandmann@sheffield.ac.uk</ext-link></corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2005</year></pub-date><pub-date pub-type="epub"><day>15</day><month>7</month><year>2005</year></pub-date><volume>76</volume><volume-id pub-id-type="other">76</volume-id><volume-id pub-id-type="other">76</volume-id><issue>8</issue><issue-id pub-id-type="other">jnnp;76/8</issue-id><issue-id pub-id-type="other">8</issue-id><issue-id pub-id-type="other">76/8</issue-id><fpage>1058</fpage><history><date date-type="accepted"><day>11</day><month>05</month><year>2005</year></date><date date-type="received"><day>03</day><month>12</month><year>2004</year></date><date date-type="rev-recd"><day>29</day><month>04</month><year>0000</year></date></history><permissions><copyright-statement>Copyright 2005 Journal of Neurology Neurosurgery and Psychiatry</copyright-statement><copyright-year>2005</copyright-year></permissions><self-uri content-type="pdf" xlink:role="full-text" xlink:href="jnnp-76-1058.pdf"></self-uri><abstract xml:lang="en"><p>Parkinson’s disease and Huntington’s disease are both model diseases. Parkinson’s disease is the most common of several akinetic-rigid syndromes and Huntington’s disease is only one of an ever growing number of trinucleotide repeat disorders. Molecular genetic studies and subsequent molecular biological studies have provided fascinating new insights into the pathogenesis of both disorders and there is now real hope for disease modifying treatment in the not too distant future for patients with Parkinson’s disease or Huntington’s disease.</p></abstract><kwd-group kwd-group-type="ABR" xml:lang="en"><kwd>A-S, α-synuclein</kwd><kwd>COX2, cyclo-oxygenase 2</kwd><kwd>CBP, CREB binding protein</kwd><kwd>MPTP, 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine</kwd></kwd-group><kwd-group kwd-group-type="KWD" xml:lang="en"><kwd>genetics</kwd><kwd>Huntington’s disease</kwd><kwd>Parkinson’s disease</kwd></kwd-group></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease</title></titleInfo><name type="personal"><namePart type="given">S M</namePart><namePart type="family">Hague</namePart><affiliation>Academic Neurology Unit, Division of Genomic Medicine, University of Sheffield, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Klaffke</namePart><affiliation>Academic Neurology Unit, Division of Genomic Medicine, University of Sheffield, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O</namePart><namePart type="family">Bandmann</namePart><affiliation>Academic Neurology Unit, Division of Genomic Medicine, University of Sheffield, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="review-article"></genre><subject><genre>hwp-journal-coll</genre><topic>Drugs: CNS (not psychiatric)</topic></subject><originInfo><publisher>BMJ Publishing Group Ltd</publisher><dateIssued encoding="w3cdtf">2005-08</dateIssued><dateCreated encoding="w3cdtf">2005-07-15</dateCreated><copyrightDate encoding="w3cdtf">2005</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Parkinson’s disease and Huntington’s disease are both model diseases. Parkinson’s disease is the most common of several akinetic-rigid syndromes and Huntington’s disease is only one of an ever growing number of trinucleotide repeat disorders. Molecular genetic studies and subsequent molecular biological studies have provided fascinating new insights into the pathogenesis of both disorders and there is now real hope for disease modifying treatment in the not too distant future for patients with Parkinson’s disease or Huntington’s disease.</abstract><note type="author-notes">Correspondence to:
Dr Oliver Bandmann
Academic Neurology Unit, E Floor Medical School, Beech Hill Road, Sheffield S10 2RX, UK; o.bandmann@sheffield.ac.uk</note><subject lang="en"><genre>ABR</genre><topic>A-S, α-synuclein</topic><topic>COX2, cyclo-oxygenase 2</topic><topic>CBP, CREB binding protein</topic><topic>MPTP, 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine</topic></subject><subject lang="en"><genre>KWD</genre><topic>genetics</topic><topic>Huntington’s disease</topic><topic>Parkinson’s disease</topic></subject><relatedItem type="host"><titleInfo><title>Journal of Neurology, Neurosurgery & Psychiatry</title></titleInfo><titleInfo type="abbreviated"><title>J Neurol Neurosurg Psychiatry</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0022-3050</identifier><identifier type="eISSN">1468-330X</identifier><identifier type="PublisherID-hwp">jnnp</identifier><identifier type="PublisherID-nlm-ta">J Neurol Neurosurg Psychiatry</identifier><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>1058</start></extent></part></relatedItem><identifier type="istex">D540A881E7B65944EF4F038D17C4DC24937CAE4C</identifier><identifier type="DOI">10.1136/jnnp.2004.060186</identifier><identifier type="href">jnnp-76-1058.pdf</identifier><identifier type="PMID">16024878</identifier><identifier type="local">0761058</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright 2005 Journal of Neurology Neurosurgery and Psychiatry</accessCondition><recordInfo><recordContentSource>BMJ</recordContentSource></recordInfo></mods></metadata><annexes><json:item><original>true</original><mimetype>image/jpeg</mimetype><extension>jpeg</extension><uri>https://api.istex.fr/document/D540A881E7B65944EF4F038D17C4DC24937CAE4C/annexes/jpeg</uri></json:item></annexes><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D74 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002D74 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:D540A881E7B65944EF4F038D17C4DC24937CAE4C
|texte= Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease
}}
| This area was generated with Dilib version V0.6.23. |  |